Machine learning predictor to investigate treatment modalities and overall survival in HER2+ early-stage breast cancer

This is like a very smart calculator built from real patient histories that estimates how long a HER2-positive early-stage breast cancer patient is likely to live under different treatment options, so doctors and drug developers can see which approaches tend to work best for which patients.